ENTRADA THERAPEUTICS INC (TRDA)
Health Care · Clinical-stage genetic medicines and oligonucleotide therapeutics · NASDAQ
Entrada is a clinical-stage biotech advancing exon-skipping genetic medicines with proprietary endosomal escape technology to treat neuromuscular diseases like DMD, with multiple programs in Phase 1/2 trials and an partnership with Vertex on a DM1 therapy.
What ENTRADA THERAPEUTICS INC does
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to engage intracellular targets that have historically been inaccessible. The company is advancing a robust portfolio of exon-skipping therapies targeting Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), as well as inherited retinal diseases including Usher syndrome, utilizing proprietary endosomal escape technology and oligonucleotide-based approaches.
Themes: Duchenne muscular dystrophy (DMD), Myotonic dystrophy type 1 (DM1), Inherited retinal diseases, Genetic medicines, Exon-skipping / splice modulation, Rare pediatric diseases, Neuromuscular disorders
Fundamentals
- Price$7.57 as of 2026-08-21 close
- Market cap$295M as of 2026-08-21
- 1-year return+29.0% 2025-08-21 close $5.87 → 2026-08-21 close $7.57
- P/En/a negative earnings
- Net margin-3537.7% as of 2026-08-24
- ROE-57.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-94.1% as of 2026-08-24
- Revenue CAGR (3y)-55.6% SEC XBRL
- Beta-0.26 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How TRDA compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ENTRADA THERAPEUTICS INC looks technically
ENTRADA THERAPEUTICS INC (TRDA) is trading 22.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 41 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 54.0% below its highest point of the past year. Trading volume is unusually light — only about 36% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 22.0% below its 200-day average, the long-term trend line — a long-term downtrend | -21.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.00 | $7.00 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.70 | $9.70 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 7.97. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 41 trading days ago — a "death cross", a bearish long-term signal | 41 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 26.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($6.74 to $7.97) — its "stochastic" reading is 67 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 67.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 17 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.45 | $16.45 |
|---|---|---|
| From the 52-week high | it is 54.0% below its 52-week high (its highest price of the past year) | -54.0% |
| Above the 52-week low | it is 50.8% above its 52-week low (its lowest price of the past year) | +50.8% |
| Below the 52-week high | it is 54.0% below its highest point of the past year | 54.0% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $24.38 (set on 2022-10-31) | $24.38 |
| Given back of the 52-week move | over the past year its closes ranged ($5.06 to $16.03), and it has given back well over two thirds of its rise from last year’s low — 77% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.90 to $9.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 77.1% |
| From the all-time high | it is 68.9% below its all-time high | -69.0% |
| Nearest price level | it is sitting right on a resistance level at $7.58 — a price it turned at twice since 2025-07-09, most recently on 2025-10-28. Since 2024-08-21 it has 4 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.1% |
| All-time low | its lowest closing price on record is $4.93 (set on 2025-08-11) | $4.93 |
| Above the all-time low | it is 53.5% above its all-time low | +53.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 61st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4706 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4706 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.08 and $8.06 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.08 – $7.07 – $8.06 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 4.5 daily ranges below its 200-day average price (22.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 36% of its 30-day average | 0.36× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.3% since the prior reading | +1.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 3.0% above the previous close 2 sessions ago and has not traded back through the level it left behind at 7.27 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.0% |
| Gap filled | a 3.2% gap up opened on 2026-08-05 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -2.7% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 14.9 percentage points (the stock gained 17.2% while the market gained 2.3%) | +14.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.9 percentage points (the stock gained 20.0% while the market gained 3.1%) | +16.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 44.0 percentage points (the stock lost 32.9% while the market gained 11.1%) | -44.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 8.5 percentage points (the stock gained 29.0% while the market gained 20.5%) | +8.5% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 52.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $8.80 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -14.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $7.23 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +4.7% |
Price levels it has turned at before
TRDA last closed at $7.57 on 2026-08-21. Since 2024-08-21 it has turned at 4 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.58 | Resistance | 0.1% above the last close | turned there twice · 2025-07-09 to 2025-10-28 |
| $6.86 | Support | 9.4% below the last close | turned there twice · 2025-07-30 to 2025-10-09 |
| $6.11 | Support | 19.4% below the last close | turned there twice · 2025-07-21 to 2025-11-06 |
| $9.40 | Resistance | 24.1% above the last close | turned there three times · 2025-05-01 to 2026-01-12 |
| $5.74 | Support | 24.2% below the last close | turned there three times · 2026-05-07 to 2026-07-28 |
| $9.81 | Resistance | 29.7% above the last close | turned there twice · 2026-01-02 to 2026-02-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $7.97.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$19.00 range $11.00 – $25.00; median $20.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TRDA
- Consensus EPS estimate-$0.98 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no approved products and no revenue; success depends entirely on clinical trial outcomes and regulatory approval of experimental programs, with substantial uncertainty as to whether any candidate will ever reach commercialization.","Intensive cash burn ($254.9M in cash and equivalents as of Q1 2026 projected to fund operations only into Q3 2027) creates significant financing risk and dilution potential if additional capital is required.","Dependence on partnerships (notably Vertex for VX-670) and regulatory pathways; delays, failures, or adverse data from any clinical program could materially impair the company's value and future prospects."]
What changed in the latest 10-Q
AI-assisted comparison of TRDA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report filed February 26, 2026 (vs. February 27, 2025 in older)
- Newer filing includes statement: 'In 2026, we expect to focus on progressing our ENTR-601-44 and ENTR-601-45 clinical trials'
- Newer filing states cash, cash equivalents and marketable securities of $254.9 million as of March 31, 2026 (vs. $326.8 million as of September 30, 2025)
- Newer filing adds: 'we expect to have four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51, which has completed IND-enabling studies but has not yet filed a regulatory application)'
- Newer filing adds: 'When combined, we estimate that there are over 11,500 patients in the U.S. and Europe that carry mutations amenable to Entrada's current exon skipping programs'
- Newer filing adds detailed ELEVATE-44-201 results: 'Cohort 1 of the study met its primary goal of favorable safety and tolerability, while also demonstrating (post hoc analysis) significant improvements in functional benefit as measured by change in Time to Rise (TTR) velocity from baseline, versus minimal clinically important difference (MCID)'
- Newer filing adds: 'In February 2026, an independent Data Monitoring Committee (DMC) reviewed the data to date from the eight patients enrolled in Cohort 1 and recommended initiation of Cohort 2 at the increased dose of 12 mg/kg without protocol modification'
- Newer filing adds: 'Additionally, in December 2025, the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to ENTR-601-44'
- Newer filing adds ELEVATE-44-102 statement: 'Following a review of safety, pharmacokinetic and pharmacodynamic data from Cohort 1 of the ELEVATE-44-201 study in the U.K and EU, we may have an opportunity to re-engage with the FDA to discuss increasing the planned doses in this clinical trial'
- Newer filing adds for ELEVATE-45-201: 'The Company completed enrollment and initiated patient dosing in Cohort 1'
- Newer filing adds for ELEVATE-45-201: 'We expect ENTR-601-45 to be both best in class and to be the first PMO-conjugate to generate clinically meaningful data in a population where only low single digit competitive dystrophin production has been observed to date'
- Newer filing adds for ELEVATE-50-201: 'The Company received regulatory authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate a Phase 1/2 MAD clinical study'
- Newer filing adds for ELEVATE-50-201: 'We are evaluating a variety of options to optimize clinical study execution including pursuing a platform or basket based approach, should either pathway become available'
- Newer filing adds for ENTR-601-51: 'The Company has completed CTA-enabling studies for people living with DMD who are amenable to exon 51 skipping, which is applicable to the largest sub-population of exon skipping amenable patients. We are reviewing our global regulatory strategy of the program to determine how best to accelerate time to full, as opposed to accelerated, approval'
- Removed:
- Older filing's description of EEV™-therapeutics and their design to enable efficient intracellular delivery is removed/simplified in newer filing
- Older filing's reference to 'RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases' is simplified to 'genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases' in newer filing
- Older filing's statement 'We currently have two product candidates, ENTR-601-44 and ENTR-601-45, in clinical development and have filed for UK regulatory clearance for a third, ENTR-601-50, in the third quarter of 2025' is removed
- Older filing's expectation 'We expect to file for EU regulatory clearance in the second half of 2026 and initiate the study by the end of 2026' is removed from overview section
- Older filing's statement 'We reported positive preliminary data in healthy volunteers from a Phase 1 clinical trial of ENTR-601-44 in 2024' is removed
- Older filing's statement 'have fully enrolled the first cohort of patients in the global Phase 1/2 multiple ascending dose (MAD) portion of the study and anticipate reporting data in the second quarter of 2026' is replaced with completed/transitioned language
- Older filing's statement 'We have dosed the first patient in our Phase 1/2 clinical trial for ENTR-601-45' is removed
- Older filing's 'Key business updates include:' section header and 'Development Pipeline' subsection structure is removed
- Older filing's detailed bullet points for ELEVATE-44-201, ELEVATE-44-102, ELEVATE-45-201, and ENTR-601-50/51 are removed/restructured
- Older filing's separate 'Beyond DMD' section with VX-670 and ocular franchise information is removed from this section
- Older filing's statements about ocular programs and expectation to 'share our first clinical candidate in ocular disease later in 2025' are removed
- Older filing's 'Components of Our Results of Operations' and 'Revenue' and 'Operating Expenses' sections are removed (text truncates)
- Reworded:
- Older: 'establishing a new class of medicines that engage intracellular targets' vs. Newer: 'establishing a new class of medicines that engx`age intracellular targets' (appears to be a transcription error in newer)
- Older describes programs as 'RNA- and protein-based programs' vs. Newer describes as 'genetic medicines'
- Older references 'ocular diseases' vs. Newer references 'inherited retinal diseases'
- Older states 'By year end, we expect to have three clinical-stage programs in our DMD franchise' vs. Newer states 'In 2026, we expect to have four clinical-stage programs in our DMD franchise'
- Older's clinical trial descriptions use past tense 'Completed enrollment of Cohort 1' vs. Newer uses 'The Company completed Cohort 1' with additional detail on outcomes
- Older: 'An independent Data Monitoring Committee (DMC) has reviewed initial data' vs. Newer: 'In February 2026, an independent Data Monitoring Committee (DMC) reviewed the data'
- Older refers to 'ENTR-601-50 and ENTR-601-51' together in one bullet vs. Newer separates them into distinct sections (ELEVATE-50-201 and ENTR-601-51)
- Older: 'Entered the study by the end of 2026' vs. Newer: 'obtained authorization' for ELEVATE-50-201
- Notes:
- Newer filing text appears truncated at end of ENTR-601-51 section ('We expect to provide more specific timeline' incomplete)
- Older filing text also appears truncated at end ('expenses incurred under agreements with third parties, s')
- One apparent OCR/transcription error in newer filing: 'engx`age' should likely be 'engage'
- Comparison limited by truncation of both documents; Components of Results of Operations section only partially present in older filing
Risk Factors
- Added:
- Added reference to ENTR-601-51 as a program in clinical development stage or having completed CTA enabling studies (newer filing)
- Added description of clinical trial activity: 'the first cohort of a Phase 1/2 clinical trial in the UK and the EU' (newer filing)
- Updated accumulated deficit amount to $312.8 million as of March 31, 2026 (newer filing)
- Removed:
- Removed language 'are in the clinical development stage' applying to all four programs ENTR-601-44, ENTR-601-45, ENTR-601-50 and VX-670 (older filing had this specific phrasing)
- Removed 'many other programs' descriptor for preclinical/discovery stage programs (older filing)
- Removed phrase 'the only clinical trial we have completed is our Phase 1 clinical trial of ENTR-601-44 in healthy volunteers in the UK' (older filing)
- Removed accumulated deficit amount of $233.9 million as of September 30, 2025 (older filing)
- Reworded:
- Changed 'ENTR-601-50 and our partnered candidate VX-670, are in the clinical development stage' to 'ENTR-601-50, ENTR-601-51 and our partnered candidate VX-670 are in the clinical development stage or have completed CTA enabling studies' (newer filing clarifies status of programs and adds ENTR-601-51)
- Changed 'we have many other programs in the preclinical development' to 'we have additional programs in the preclinical development' (newer filing)
- Changed 'based on our EEV Platform is unproven' to 'that are based on our EEV Platform is unproven' (newer filing adds 'that are')
- Changed 'As an organization, the only clinical trial we have completed is our Phase 1 clinical trial of ENTR-601-44 in healthy volunteers in the UK, and we have not completed' to 'As an organization, we have only completed a Phase 1 clinical trial of ENTR-601-44 in healthy volunteers in the UK and the first cohort of a Phase 1/2 clinical trial in the UK and the EU, and we have not completed' (newer filing expands clinical trial description)
- Notes:
- Older filing text appears truncated at the end ('fluctua'); comparison is based on complete sections available
- The accumulation of changes relates to updated clinical trial progress and updated financial metrics reflecting passage of time between filing dates (November 2025 vs. May 2026)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 9 sells ($3M) — 2 selling insiders
- Last 90 days0 buys · 9 sells ($3M) — 2 selling insiders
- Last 180 days1 buy ($29316) · 16 sells ($4M) — 1 buying, 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-10. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TRDA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding TRDA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,326,636
- Reported value $41,982,146
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TRDA had 2,143,736 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TRDA had 5.51% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.33 days to cover at the same settlement.
- Reported short interest (shares) 2,143,736
- Short interest (% of shares outstanding) 5.51%
- Prior settlement (shares) 2,230,697
- Reported change -3.9%
- Days to cover (reported) 4.33
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sarepta Therapeutics (SRPT)
- Wave Life Sciences (WVE)
- NS Pharma (part of Nippon Shinyaku)
- Vertex Pharmaceuticals (VRTX)
- Biogen (BIIB)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TRDA vs…
Frequently asked questions
What does ENTRADA THERAPEUTICS INC (TRDA) do?
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines designed to engage intracellular targets that have historically been inaccessible. The company is advancing a robust portfolio of exon-skipping therapies targeting Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), as well as inherited retinal diseases including Usher syndrome, utilizing proprietary endosomal escape technology and oligonucleotide-based approaches.
What sector is ENTRADA THERAPEUTICS INC (TRDA) in?
ENTRADA THERAPEUTICS INC (TRDA) is classified in the Health Care sector. Its industry is Clinical-stage genetic medicines and oligonucleotide therapeutics. It trades on NASDAQ.
Who are ENTRADA THERAPEUTICS INC's (TRDA) competitors?
Notable peers of ENTRADA THERAPEUTICS INC (TRDA) include Sarepta Therapeutics, Wave Life Sciences, NS Pharma (part of Nippon Shinyaku), Vertex Pharmaceuticals and Biogen. This peer set is informational only — not financial advice.
Is ENTRADA THERAPEUTICS INC (TRDA) overbought or oversold right now?
ENTRADA THERAPEUTICS INC (TRDA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TRDA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.